Slides
Page 1
NU SKIN Q2 2026 Financial Overview
Page 2
Important Information Regarding Forward-Looking Statements: This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company’s current expectations and beliefs. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws and include, but are not limited to, statements of management’s expectations regarding the company’s performance, growth, initiatives, strategic priorities, cost optimization, shareholder value, initiatives, sales force, initiatives to gro w and develop our sales channel, product strategy, Prysm iO launch and its timing, Prysm iO’s features and potential benefits to the business, launches of products and technology tools, future uses and benefits of artif icial intelligence, emerging-market strategy, timing and benefits of launching our business in India, east-west realignment of our business and its timing and cost savings; projections regarding revenue, expenses, margins, tax rates, profitability, earnings per share, foreign currency fluctuations, financial position, deferred tax assets, uses of cash and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as “believe,” “expect,” “vision,” “improve,” “expand,” “increase,” “anticipate,” “plan,” “continue,” “introduce,” “outlook,” “guidance,” “project,” “forecast,” “priority,” “will,” “would,” “could,” “may,” “might,” the negative of these words and other similar words. The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outco mes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following: • any failure of current or planned initiatives or products to generate interest among the company’s sales force and customers and generate sponsoring and selling activities on a sustained basis; • risk that direct selling laws and regulations in any of the company’s markets, including the United States and Mainland China , may be modified, interpreted or enforced in a manner that results in negative changes to the company’s business model or negatively impacts its revenue, sales force or business, including throug h the interruption of sales activities, loss of licenses, increased scrutiny of sales force actions, imposition of fines, or any other adverse actions or events; • economic conditions and events globally; • the company’s future tax-planning initiatives, any prospective or retrospective increases in duties or tariffs on the company’s products imported into the company’s markets, and any adverse results of tax audits or unfavorable changes to tax laws in the company’s various markets; • competitive pressures in the company’s markets; • risk that epidemics or other crises, as well as any related disruptions, could negatively impact our business; • adverse publicity related to the company’s business, products, industry or any legal actions or complaints by the company’s s ales force or others; • political, legal, tax and regulatory uncertainties, including trade policies, associated with operating in Mainland China and other international markets; • uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consum er sentiment in Mainland China on our business operations and results; • risk of foreign-currency fluctuations and the currency translation impact on the company’s business associated with these fluctuations; • uncertainties regarding the future financial performance of the businesses the company has acquired; • risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initia tives or launch strategies, and increased risk of inventory write -offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies; and • regulatory risks associated with the company’s products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements. The company’s financial performance and the forward-looking statements contained herein are further qualified by a detailed disc ussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company’s beliefs as of the date that such information was first provided, and the company assumes no duty to update the forward-looking statements contained in this presentation to reflect any change except as required by law.
Page 3
Q2 Overview 14% 8% 19% 10%8% 14% 12% 15% Q2 Revenue Distribution Mainland China Americas South Korea Southeast Asia / Pacific Japan Europe & Africa Hong Kong / Taiwan RhyzRevenue $320.1 million, (17.1%) YOY (1.0)% FX impact or $4M EPS $(5.14) or $0.20 excluding non-cash impairment and non-cash tax charges compared to $0.43 Customers (14)%, Paid Affiliates (8)%, Sales Leaders (9)%, YOY
Page 4
Customer/Paid Affiliates/Sales Leader Performance Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Sales Leaders Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Affiliates Q2 24 Q3 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Customers Market Customers YOY % Change Paid Affiliates YOY % Change Sales Leaders YOY % Change Mainland China 103,891 (11%) 18,736 (3%) 5,899 2% Americas 183,757 (24%) 27,337 (5%) 5,041 (16%) Korea 54,305 (19%) 14,826 (13%) 2,571 (16%) S.E. Asia and Pacific 69,354 (5%) 17,677 (16%) 3,631 (12%) Japan 100,849 (5%) 19,018 (3%) 5,782 (2%) Hong Kong/ Taiwan 36,549 (12%) 9,390 (2%) 1,858 (10%) Europe & Africa 111,332 (12%) 13,307 (13%) 2,216 (18%) Total 660,037 (14%) 120,291 (8%) 26,998 (9%) Q2 2026 vs Q2 2025
Page 5
Q2 Revenue by Segment (M) $46.0 $59.8 $25.6 $43.3 $38.1 $26.1 $32.3 $48.9 Mainland China (-14%) Americas (-18%) South Korea (-25%) Southeast Asia / Pacific (-15%) Japan (-14%) Hong Kong/Taiwan (-5%) Europe & Africa (-13%) Rhyz (-25%) Q2 25 Q2 26
Page 6
Customers by Segment 103,891 183,757 54,305 69,354 100,849 36,549 111,332 Mainland China (-11%) Americas (-24%) South Korea (-19%) Southeast Asia / Pacific (-5%) Japan (-5%) Hong Kong / Taiwan (-12%) Europe & Africa (-12%) Q2 25 Q2 26
Page 7
Paid Affiliates by Segment 18,736 27,337 14,826 17,677 19,018 9,390 13,307 Mainland China (-3%) Americas (-5%) South Korea (-13%) Southeast Asia / Pacific (-16%) Japan (-3%) Hong Kong / Taiwan (-2%) Europe & Africa (-13%) Q2 25 Q2 26
Page 8
Sales Leaders by Segment 5,899 5,041 2,571 3,631 5,782 1,858 2,216 Mainland China (2%) Americas (-16%) South Korea (-16%) Southeast Asia / Pacific (-12%) Japan (-2%) Hong Kong / Taiwan (-10%) Europe & Africa (-18%) Q2 25 Q2 26
Page 9
Q2 2026 Operational Performance 27.6% 28.4% Q2 25 Q2 26 G&A Expense 33.2% 33.7% Q2 25 Q2 26 Selling Expenses 8.0% -18.5% Q2 25 Q2 26 *Operating Margin 68.8% 68.2% Q2 25 Q2 26 Gross Margin Nu Skin business was 77.5% in 2025 compared to 77.7% in 2026 Nu Skin business was 40.0% in 2025 compared to 39.8% in 2026 * Percentages reflect US GAAP , see reconciliation table for non-GAAP #’s
Page 10
Q3 & 2026 Outlook $489 $417 $439 $430 $446 $386 $364 $370 $320 $320 $310- $340 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26 Quarterly Revenue Q3 26 Revenue • $310 to $340 million; (15)% to (7)% • Approx. (3)% to (2)%FX impact Q3 26 EPS • $0.00 to $0.09 or $0.10 to $0.20 on an adjusted basis 2026 Revenue • $1.28 to $1.35 B; (14)% to (9)% • Approx. (1)% FX impact 2026 EPS • $(4.90) to $(4.73) or $0.70 to $0.90 on an adjusted basis
Page 11
Reconciliation Tables NU SKIN ENTERPRISES, INC. Reconciliation of Operating Margin Excluding Certain Charges to GAAP Operating Margin (in thousands, except for per share amounts) Three months ended June 30, Six months ended June 30, 2026 2025 2026 2025 Operating Income $ (59,319) $ 30,780 $ (55,293) $ 20,877 Impact of inventory write-off - - 3,116 - Impact of other charges(1) - - 2,643 7,966 Impact of impairment 78,875 - 80,714 25,114 Adjusted operating income $ 19,556 $ 30,780 $ 31,180 $ 53,957 Operating margin (18.5)% 8.0% (8.6)% 2.8% Operating margin, excluding certain charges 6.1% 8.0% 4.9% 7.2% Revenue $ 320,112 $ 386,138 $ 640,720 $ 750,628 (1) Other charges for the first quarter of 2026 consist of $1.0 million related to the wind down of the separate BeautyBio business and $1.6 million of other employee severance charges. Other charges for the first quarter of 2025 consist of expenses incurred in connection with the Mavely sale, including $2.7 million of transaction bonuses for certain employees and $5.2 million of equity compensation as a result of the vesting of th e Mavely profits interest units.
Page 12
Reconciliation Tables NU SKIN ENTERPRISES, INC. Reconciliation of Effective Tax Rate Excluding Impact of Certain Charges to GAAP Effective Tax Rate (in thousands, except for per share amounts) Three months ended June 30, Six months ended June 30, 2026 2025 2026 2025 Provision (benefit) for income taxes $ 186,623 $ 6,292 $ 187,386 $ 33,378 Impact of inventory write-off on provision for income taxes - - 1,065 - Impact of other charges(1) on provision for income taxes - - 903 725 Impact of impairment on provision for income taxes (13,370) - (12,741) 5,433 Impact of gain on Mavely sale on provision for income taxes - - - (31,104) Impact of gain on unrealized investment loss on provision for income taxes - - - 6,074 Impact of valuation allowance on deferred tax assets (167,505) - (167,505) - Provision for income taxes, excluding impact of certain charges $ 5,748 $ 6,292 $ 9,108 $ 14,506 Income before provision for income taxes (63,175) 27,411 (60,576) 162,012 Impact of inventory write-off - - 3,116 - Impact of other charges(1) - - 2,643 7,966 Impact of impairment expense: 78,875 - 80,714 25,114 Impact of gain on Mavely sale - - - (176,162) Impact of unrealized investment loss - - - 28,077 Income before provision for income taxes, excluding impact certain charges $ 15,700 $ 27,411 $ 25,897 $ 47,007 Effective tax rate (295.4)% 23.0% (309.3)% 20.6% Effective tax rate, excluding impact of certain charges 36.6% 23.0% 35.2% 30.9%
Page 13
Reconciliation Tables NU SKIN ENTERPRISES, INC. Reconciliation of Earnings Per Share Excluding Impact of Certain Charges to GAAP Earnings Per Share (in thousands, except for per share amounts) Three months ended June 30, Six months ended June 30, 2026 2025 2026 2025 Net income $ (249,798) $ 21,119 $ (247,962) $ 128,634 Impact of Inventory write-off Inventory write-off - - 3,116 - Tax impact - - (1,065) - Impact of other charges Other charges - - 2,643 7,966 Tax impact - - (903) (725) Impact of impairment Impairment charges 78,875 - 80,714 25,114 Tax impact 13,370 - 12,741 (5,433) Impact of Mavely sale Mavely sale - - - (176,162) Tax impact - - - 31,104 Impact of unrealized investment loss Unrealized investment loss - - - 28,077 Tax impact - - - (6,074) Impact of valuation allowance on deferred tax assets 167,505 - 167,505 - Adjusted net income $ 9,952 $ 21,119 $ 16,789 $ 32,501 Diluted earnings per share $ (5.14) $ 0.43 $ (5.12) $ 2.59 Diluted earnings per share, excluding impact of certain charges $ 0.20 $ 0.43 $ 0.35 $ 0.65 Weighted-average common shares outstanding (000) 48,596 49,499 48,400 49,748
Page 14
Reconciliation Tables NU SKIN ENTERPRISES, INC. Reconciliation of Earnings Per Share Excluding Impact of Certain Charges to GAAP Earnings Per Share Three months ended September 30, 2026 Year ended December 31, 2026 Low end High end Low end High end Earnings Per Share $ 0.00 $ 0.09 $ (4.86) $ (4.69) Impact of inventory write-off Inventory write-off - - 0.06 0.06 Tax impact - - (0.02) (0.02) Impact of other charges Other charges(2) 0.10 0.10 0.15 0.15 Tax impact (0.02) (0.02) (0.04) (0.04) Impact of impairment: Impairment charges - - 1.67 1.67 Tax impact - - 0.26 0.26 Impact of valuation allowance on deferred tax assets 0.02 0.03 3.52 3.55 Adjusted EPS $ 0.10 $ 0.20 $ 0.70 $ 0.90 (2) We are currently anticipating other charges for the third quarter of 2026 of approximately $5 million in cash -based transition cost. Other charges for the first quarter of 2026 consist of $1.0 million related to the wind down of the separate BeautyBio business and $1.6 million of other employee severance charges.